I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents

Washington, D.C. 20231 On May 29, 2001

TOWNSEND and TOWNSEND and CREW LLP

Attorney Docket No.: 018941000411 Client Reference No.: B98-002

RECEIVED

JUN 0 8 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Duffy, Patricia A.

Art Unit:

1645

AMENDMENT

In re application of:

STEPHENS et al.

Application No.: 09/438,185

Filed: November 11, 1999

For: CHLAMYDIA PNEUMONIAE

GENOME SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 27, 2001, applicants hereby elect with traverse Group II (claims 9) directed to polypeptides encoded by Chlamydia pneumoniae genome sequence. In addition, applicants elect SEQ ID NO: 1047 (CPn 1046).

According to the MPEP, where claims can be examined together without undue burden, the Examiner must examine the claims on the merits even though they are directed to independent and distinct inventions. See, the MPEP at 803.01. In establishing that an "undue burden" would exist for co-examination of claims, the Examiner must show that examination of the claims would involve substantially different prior art searches, making the co-examination burdensome. Applicants respectfully submit that examination of all the claims in the present application would not create an undue burden and respectfully request withdrawal of the restriction requirement in this case.

STEPHENS et al. Application No.: 09/438,185 Page 2

SF 1229381 v1

If a telephone conference would expedite prosecution of this application, the

Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,

Kevin Bastian Reg No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 Tel: (415) 576-0200 Fax: (415) 576-0300 KLB